TRK Inhibitors: A Tumor Agnostic Approach to Treatment of Solid Tumors
EP. 1: TRK as Ideal Candidate for Targeted Therapy
July 15th 2019
EP. 2: Scientific Rationale for Development of TRK Inhibitors
July 15th 2019
EP. 3: Early Development of TRK Inhibitor-Larotrectinib
July 15th 2019
EP. 4: Efficacy of TRKi-Larotrectinib Among Tumor Types
July 15th 2019
EP. 5: Safety and Efficacy Profile for TRKi-Larotrectinib
July 15th 2019
EP. 6: Patient Selection for TRKi-Larotrectinib
July 15th 2019
EP. 7: TRKi: High Response Rate in Patients With Primary CNS Disease
July 15th 2019
EP. 8: Entrectinib-A Multitargeted TKI
July 15th 2019
EP. 9: Entrectinib-Selective ROS Inhibition
July 15th 2019
EP. 10: Investigational Approaches for TRK-Fusion Cancers
July 15th 2019
EP. 11: NGS Testing to Detect TRK Fusions
July 15th 2019
EP. 12: Molecular Testing for RAI-Refractory Thyroid Cancer
July 15th 2019
EP. 13: Dirty Kinases in TRK-Fusion Malignancies
July 15th 2019
